A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter Type 2, in Healthy Individuals at Steady State
IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045.
Diabetes Res Clin Pract. 2018; 138: 271-281
Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases.
Diabetol Metab Syndr. 2019; 11: 80
China national diabetes and metabolic disorders study group. Prevalence of diabetes among men and women in China.
N Engl J Med. 2010; 362: 1090-1101
Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus.
Clin Pharmacol. 2019; 11: 57-65
Treatment and diagnosis of diabetes mellitus and its complication: advanced approaches.
Mini Rev Med Chem. 2015; 15: 1132-1133
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the study of diabetes.
Diabetes Care. 2009; 32: 193-203
CDA 2008 Clinical Practice Guidelines Steering Committee. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes: response to Nathan et al.
Diabetes Care. 2009; 32 (): e34
The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Annu Rev Med. 2015; 66: 255-270
Mechanisms of protective effects of SGLT2 inhibitors in cardiovascular disease and renal dysfunction.
Curr Top Med Chem. 2019; 19: 1818-1849
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Drugs. 2015; 75: 33-59
Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
Diabetes Obes Metab. 2015; 17: 42-51
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Lancet. 2010; 375: 2223-2233
Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
J Med Chem. 2010; 53: 6355-6360
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
Diabetes Obes Metab. 2011; 13: 669-672
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
BMJ Open. 2019; 9e022577
Applications of human pharmacokinetic prediction in first-in-human dose estimation.
AAPS J. 2012; 14: 262-281
Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus.
Diabetes Obes Metab. 2019; ()https://doi.org/10.1111/dom.13887
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
Clin Pharmacol Ther. 2009; 85: 513-519
LOWESS: a program for smoothing scatterplots by robust locally weighted regression.
The Am Statistician. 1981; 35: 54
Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study.
Curr Ther Res Clin Exp. 2017; 87: 13-19
Population pharmacokinetic analysis of dapagliflozin in healthy subjects and patients with type 2 diabetes mellitus.
Clin Pharmacol Ther. 2010; 83: S93
Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus.
J Pharm Pharmacol. 2018; 70: 855-864
Association of variability and pharmacogenomics with bioequivalence of gefitinib in healthy male subjects.
Front Pharmacol. 2018; 9: 849
Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes–results of a hyperglycaemic glucose clamp study.
Nephrol Dial Transpl. 2006; 21: 2166-2171
Safety and efficacy of empagliflozin as add-on therapy to GLP-1 receptor agonist (liraglutide) in Japanese patients with type 2 diabetes mellitus: a randomised, double-blind, parallel-group Phase 4 study.
Diabetes Ther. 2019; 10: 951-963
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
Br J Clin Pharmacol. 2013; 76: 432-444
Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
Diabetes Obes Metab. 2011; 13: 357-365
Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
J Clin Pharmacol. 2013; 53: 601-610
The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
Expert Opin Drug Metab Toxicol. 2018; 14: 1287-1302
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis.
Diabetes Obes Metab. 2019; 21: 1237-1250
Mechanism-based pharmacokinetic-pharmacodynamic modeling of luseogliflozin, a sodium glucose Co-transporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Biol Pharm Bull. 2017; 40: 1207-1218
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Cardiovasc Diabetol. 2019; 18: 20
Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.
Exp Physiol. 2016; 101: 731-742
Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
Clin Pharmacokinet. 2014; 53: 17-27
Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Diabetes Metab Res Rev. 2014; 30: 204-221